BioMarin Pharma logo

BioMarin Pharma

Stock
Stock
ISIN: US09061G1013
Ticker: BMRN
US09061G1013
BMRN

Price

Price

CHART BY

Frequently asked questions

What is BioMarin Pharma's market capitalization?

The market capitalization of BioMarin Pharma is $12.74B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is BioMarin Pharma's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for BioMarin Pharma is 40.24. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for BioMarin Pharma?

BioMarin Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1.661. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for BioMarin Pharma's stock?

Currently, 29 analysts cover BioMarin Pharma's stock, with a consensus target price of $96.20. Analyst ratings provide insights into the stock's expected performance.

What is BioMarin Pharma's revenue over the trailing twelve months?

Over the trailing twelve months, BioMarin Pharma reported a revenue of $2.75B.

What is the EBITDA for BioMarin Pharma?

BioMarin Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $490.44M. EBITDA measures the company's overall financial performance.

What is the free cash flow of BioMarin Pharma?

BioMarin Pharma has a free cash flow of $319.89M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does BioMarin Pharma have, and what sector and industry does it belong to?

BioMarin Pharma employs approximately 3,401 people. It operates in the Health Care sector, specifically within the Biotechnology industry.

What is the free float of BioMarin Pharma's shares?

The free float of BioMarin Pharma is 188.22M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$12.74B
EPS (TTM) 
$1.661
Free Float 
188.22M
P/E ratio (TTM) 
40.24
Revenue (TTM) 
$2.75B
EBITDA (TTM) 
$490.44M
Free Cashflow (TTM) 
$319.89M

Pricing

1D span
$66.82$67.15
52W span
$61.15$98.19

Analyst Ratings

The price target is $96.20 and the stock is covered by 29 analysts.

Buy

22

Hold

7

Sell

0

Information

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Employees
3,401
Industries
Biotechnology
Sector
Health Care

Identifier

ISIN
US09061G1013
Primary Ticker
BMRN

Knockouts

Join the conversation